Factors Affecting the Quality of Cryoprecipitate

Overview

Journal Asian J Transfus Sci

Specialty Hematology

Date 2017 Mar 21

PMID 28316438

Citations 1

Authors

Rajeswari Subramaniyan

Neelam Marwaha

Ashish Jain

Jasmina Ahluwalia

Affiliations

Soon will be listed here.

Abstract

Background: Many variables affect the quality of cryoprecipitate (CRYO). We investigated the effect of freezing techniques and ABO blood groups on the quality of CRYO with respect to factor VIII: C and fibrinogen levels.

Materials And Methods: Ninety-six whole blood units each collected from in-house (Group I) and blood donation camps outside the hospital premises (Group II) were processed for CRYO preparation. Within each group, half the number of plasma units was frozen using blast freezer and another half using the conventional freezer. The CRYOs from blood groups A, B, and O were equally distributed, i.e. 32 within each of the Groups I and II. The fibrinogen and factor VIII: C levels in CRYO were analyzed using single-stage clotting assay.

Results: In Group I, the mean ± standard deviation percentage recovery of factor VIII levels in CRYO prepared using the conventional freezer and blast freezer were 58.5% ±16.2% and 66.7% ±16.4%, respectively, and in Group II, it was 55.3% ±17.6% and 70.4% ±13.4%, respectively. Recovery of factor VIII was higher in CRYO prepared using blast freezer than that of CRYO prepared using conventional freezer ( < 0.000). In Group II, CRYOs prepared using blast freezer had higher percent recovery of fibrinogen than that of Group I. In both the groups, the mean factor VIII levels in blood group A were higher than that of factor VIII levels in the blood group O CRYO.

Conclusion: The factor VIII recovery in CRYO improves significantly with higher baseline factor VIII: C levels, blood group A donor, and rapid freezing using blast freezer. Rapid freezing also increases the fibrinogen yield.

Citing Articles

An insight to the internal quality control of blood components separated using the latest whole blood collection and processing systems: Experience from a tertiary care hospital blood transfusion service in Eastern India.

Das S, Biswas R, Sardar T, Safi M Asian J Transfus Sci. 2023; 16(2):194-200.

PMID: 36687542 PMC: 9855214. DOI: 10.4103/ajts.ajts_52_21.

References

Freedman M, Rock G . Analysis of the products of cryoprecipitation: RiCoF is deficient in cryosupernatant plasma. Transfus Apher Sci. 2010; 43(2):179-82. DOI: 10.1016/j.transci.2010.07.004. View

Slichter S, Counts R, Henderson R, Harker L . Preparation of cryoprecipitated factor VIII concentrates. Transfusion. 1976; 16(6):616-26. DOI: 10.1046/j.1537-2995.1976.16677060245.x. View

Omidkhoda A, Tabatabaei M, Atarodi K, Karimi K, Rahimi Froushani A, Pourfathollah A . A comparative study of the effects of temperature, time and factor VIII assay type on factor VIII activity in cryoprecipitate in Iran. Blood Transfus. 2011; 9(4):394-9. PMC: 3200408. DOI: 10.2450/2011.0064-10. View

Callum J, Karkouti K, Lin Y . Cryoprecipitate: the current state of knowledge. Transfus Med Rev. 2009; 23(3):177-88. DOI: 10.1016/j.tmrv.2009.03.001. View

Mohanty D, Ghosh K, Marwaha N, Kaur S, Chauhan A, Das K . Major blood group antigens--a determinant of factor VIII levels in blood?. Thromb Haemost. 1984; 51(3):414. View

Yazer M, Triulzi D, Hassett A, Kiss J . Cryoprecipitate prepared from plasma frozen within 24 hours after phlebotomy contains acceptable levels of fibrinogen and VIIIC. Transfusion. 2009; 50(5):1014-8. DOI: 10.1111/j.1537-2995.2009.02535.x. View

Agrawal A, Tiwari A, Mehta N, Bhattacharya P, Wankhede R, Tulsiani S . ABO and Rh (D) group distribution and gene frequency; the first multicentric study in India. Asian J Transfus Sci. 2014; 8(2):121-5. PMC: 4140055. DOI: 10.4103/0973-6247.137452. View

Carlebjork G, Blomback M, Pihlstedt P . Freezing of plasma and recovery of factor VIII. Transfusion. 1986; 26(2):159-62. DOI: 10.1046/j.1537-2995.1986.26286152906.x. View

. Variables involved in cryoprecipitate production and their effect on factor VIII activity. Report of a working party of the Regional Transfusion Directors Committee. Br J Haematol. 1979; 43(2):287-95. DOI: 10.1111/j.1365-2141.1979.tb03752.x. View

10.

Hornsey V, Krailadsiri P, MacDonald S, Seghatchian J, Williamson L, Prowse C . Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol. 2000; 109(3):665-70. DOI: 10.1046/j.1365-2141.2000.02078.x. View

11.

Yousef H, Neurath D, Freedman M, Rock G . Cryoprecipitate production: the use of additives to enhance the yield. Clin Lab Haematol. 2006; 28(4):237-40. DOI: 10.1111/j.1365-2257.2006.00785.x. View

12.

Myllyla G . Factors determining quality of plasma. Vox Sang. 1998; 74 Suppl 2:507-11. DOI: 10.1111/j.1423-0410.1998.tb05466.x. View

13.

Caudill J, Nichols W, Plumhoff E, Schulte S, Winters J, Gastineau D . Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion. 2009; 49(4):765-70. DOI: 10.1111/j.1537-2995.2008.02021.x. View

14.

Ness P, Perkins H . Fibrinogen in cryoprecipitate and its relationship to factor VIII (AHF) levels. Transfusion. 1980; 20(1):93-6. DOI: 10.1046/j.1537-2995.1980.20180125050.x. View

15.

Wensley R, Snape T . Preparation of improved cryoprecipitated factor VIII concentrate. A controlled study of three variables affecting the yield. Vox Sang. 1980; 38(4):222-8. DOI: 10.1111/j.1423-0410.1980.tb02358.x. View

16.

Farrugia A . Plasma for fractionation: safety and quality issues. Haemophilia. 2004; 10(4):334-40. DOI: 10.1111/j.1365-2516.2004.00911.x. View